Complex in vitro model developers' perspective on advanced hepatic in vitro culture methods for predictive drug safety.

INTRODUCTION: Adverse drug reactions remain a major barrier to drug development, with hepatotoxicity representing a persistent cause of clinical failure, market withdrawal, and post marketing restrictions. Global surveys report hundreds of withdrawals attributed to hepatotoxicity. Despite extensive regulatory monitoring, current hepatotoxicity assessment paradigms still fail to reliably identify hepatotoxic drug candidates before clinical trials. In parallel with continued reliance on regulatory animal testing, scientists have refined in vitro liver models over decades, progressing from perfused liver transplants to standardized and scalable cell-based systems to evaluate drug candidate safety prior to first in human studies.

AREAS COVERED: This concise review outlines key milestones in the development of cell-based hepatotoxicity platforms and highlights the long-standing tension between physiological relevance and industrial applicability. State-of-the-art culture methods applied to in vitro hepatotoxicity assessment include micropatterned co-cultures, sandwich cultures, spheroid cultures, and perfused cultures, each offering distinct strengths and weaknesses.

EXPERT OPINION: A perspective highlights key unmet needs in in vitro hepatotoxicity assessment, including rigorous method standardization, broadly accepted reference compound panels, more physiological culture conditions, and integration of data rich multimodal readouts with machine learning to strengthen human hepatotoxicity risk assessment.